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SUMMARY: Reducing the infarct size in acute myocardial infarction is one of the most important goals driving new drug
research and development. During the last two decades, many clinical studies have found cardioprotective effects of corticosteroids, but
their exact role in ischemic preconditioning remains questionable. The aim of the present study was to determine the protective effects of
hydrocortisone sodium succinate on myocardial preconditioning in rabbit hearts. Twenty-four male New Zealand rabbits were divided
randomly & equally in four groups: 1) control, 2) Infarct, 3) Ischemic preconditioning (IP) and 4) Hydrocortisone (HYD). The HYD
group received 50mg/kg Hydrocortisone 45min before major ischemia. Serum levels of cardiac troponin-T(cTNT) and cortisole were
measured before and after the protocols. Triphenyl-tetrazolium chloride staining was used to determine the infarcted area. In the present
study, exogenous hydrocortisone decreased infarct size by 53% in comparison to the infarct group. Serum level of cortisole was increased
in the IP and HYD groups, and was significant in the HYD group (p<0.01). An increasing trend in cortisole level was associated with a
decreasing trend in infarct size and cTNT in the IP and HYD groups (p>0.01). In conclusion, we showed that hydrocortisone has
cardioprotective effects when injected before the onset of myocardial infarction. In addition, we have proposed for the first time that
endogenous hydrocortisone may play a role in ischemic preconditioning phenomena.
KEY WORDS: Hydrocortisone; Infarct size; Ischemia-reperfusion model; Ischemic preconditioning; Serum cortisole.
INTRODUCTION
 Many studies have focused on finding new ways to
reduce the size of an infracted myocardium after AMI, one of
the major causes of mortality and morbidity in the Western
world (Zipes & Braunwald, 2005). In the past two decades, a
new phenomenon called  “Ischemic Preconditioning (IP)” has
aroused great interest as a method for treating AMI. The
discovery of many endogenous peptides in the IP pathway has
opened up a new perspective for pharmacologic
preconditioning by various types of drugs (Eisen et al., 2004;
Werns & Lucchesi, 1989).
Some studies have found protective effects of
corticosteroids such as dexamethasone and methylprednisolone,
when administered after coronary artery occlusion (Hafezi-
Moghadam et al., 2002; Maclean et al., 1978; Fillinger et al.,
2002; Enc et al., 2006). The later phase of myocardial cell injury,
in part, results from acute inflammatory reactions ensuing in
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the ischemic myocardium, as infarct size can be effectively
reduced by anti-inflammatory agents (Fu et al., 2007; Gross et
al., 2004; Cannon et al., 2004). Despite numerous clinical and
some experimental studies regarding the effects of
corticosteroids in reducing myocardial infarct size (Libby et
al., 1973; Hepper et al., 1955; Kilger et al., 2003; Giugliano et
al., 2003), their role in IP phenomena remains open to debate.
For example, corticosteroids given as late as 6 h after coronary
occlusion can reduce infarct size by up to 35% in comparison
with an untreated control group (Park & Lucchesi, 1999).
 Our postulate is that an increase in endogenous
hydrocortisone is correlated with a decrease in infarct size.
Our working hypotheses are that injection of exogenous
hydrocortisone before major ischemia will reduce infarct size;
and also that endogenous hydrocortisone is responsible for the
effects of IP in reducing infarct size.
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 Therefore, this study was conducted to assess
“Cardioprotective effects of exogenous and endogenous
hydrocortisone in a rabbit model of ischemia-reperfusion”.
MATERIAL AND METHOD
This study was approved by the Institutional Animal
Care and Use Committee of the Golestan University of
Medical Sciences and was performed in accordance with
the “Guide for the Care and Use of Laboratory Animals”
from National Institutes of Health (NIH Publication No. 86-
13, Revised 1996).
Animals. Male New Zealand rabbits, weighing 1.5-2.5kg
(purchased from “Iranian Pasteur Institute”, Tehran, Iran)
were used. Rabbits were kept in an animal house, with food
and water available ad libitum, under a 12 h light–dark cycle
and controlled temperature (22 ± 2°C).
Experimental Design. All 24 rabbits used in this study were
divided randomly and equally into four experimental groups:
1-Control (n=6), 2-Infarct (n=6), 3-Ischemic preconditioning
(IP) (n=6), 4-Hydrocortisone treatment (HYD) (n=6).
General anesthesia was induced by injection of
Ketamine (50mg/kg) and Xylazine (5mg/kg) intramuscularly
and maintained by intravenous (IV) injection of this mixture.
Rabbits were intubated and attached to an animal ventilator
(UGO Basile, Italy) and ventilated to receive SPO2 >95%.
In order to induce myocardial ischemia among all groups
except the control, after left thoracotomy, the left anterior
descending (LAD) coronary artery was ligated by a 3-0 silk
suture for 45min. This was followed by a 120 min reperfusion
after  loosening the snare.
In the IP group, three cycles of 5min ischemia were
followed by 10 min reperfusion before major ischemia. The
HYD group received 50mg/kg Hydrocortisone sodium
succinate (ROTEXMEDICA, Germany) by IV, 45 min
before major ischemia. At the end of reperfusion, Evans blue
dye (4%) was injected IV and hearts were removed and cut
into 4mm thick slices. After staining with Triphenyl-
tetrazoliumchloride (1%) for 20 minutes, the tissues were
fixed with buffered formaldehyde solution for another 24
hours, to determine the infarcted area (IA) and Area At Risk
(AAR).
Analytical procedures. ECG monitoring from lead II and
SPO2 monitoring (POWERLAB®, Australia) were
performed throughout the operation time. Blood samples
were taken before and after operation for measurement of
serum levels of cortisole and Cardiac Troponin- T (cTNT).
Statistical analysis. All results are presented as the
mean±SEM. Means of groups were compared by one-way
analysis of variance (ANOVA), and then post hoc analysis
(LSD test) was performed for specific group comparisons.
In order to test the correlation between cTNT-2 and IA
Volume and IA/AAR ratio, Pearson Linear Correlation was
used. The level of statistical significance was accepted as
p< 0.05. Calculations were performed using SPSS software
version 11.5 (SPSS, Chicago, IL, USA).
RESULTS
ST-segment. The increase of ST-segment elevation after
LAD ligation in the Infarct group was more than that of the
IP or HYD groups (Fig. 1). The increase among the IP group
was significantly less (p<0.001). Although the increment in
this value in the HYD group was less than in the Infarct
group, it was not statistically significant (p>0.05). In addition,
by comparing the percentage of decrement in ST-segment
elevation after 60 minutes of reperfusion, it was found that
the HYD group showed a more significant effect than did
the IP group (p<0.05).
Myocardial Infarct size. As shown in Fig. 2, the Infarcted
Area (IA) as well as the Infarcted Area Volume (IA Volume)
were decreased in both the IP and HYD groups and these
decrements were statistically different when compared to
those of the Infarct group (p<0.0001 for both). However,
there were no statistically significant differences between
the IP and HYD groups in terms of the amount of decrease
in either IA and IA volume (p>0.05). These findings revealed
a significant decrease in the ratio of IA/AAR among IP and
HYD groups in comparison to the Infarct group (p<0.05 in
IP vs. Infarct and p<0.001 in HYD vs. control). It is notable
that the decrement in the HYD group was larger than the IP
group but was not statistically significant (p>0.05) (Fig. 2).
Serum levels of cTNT. The levels of cTNT were increased
from an undetectable level (p<0.01 ng/ml) to detectable
amounts among all groups except the control.  We also found
a decrease in cTNT levels after surgery among the IP and
HYD groups in comparison to the Infarct group, which was
more prominent in HYD group (Fig. 3). Despite all of this,
there were no statistically significant differences between
the IP or HYD groups and the Infarct group or even between
IP and PP groups (p>0.05) (Fig .3).
Alterations in Serum Levels of Cortisole. There were no
significant differences among serum levels of cortisole before
the onset of surgery between groups (p>0.05). As shown in
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Fig. 4, an increase of serum levels of cortisole
was seen after the surgical process which had
been performed on all groups. However, the
increase in serum cortisole levels were greater
in the IP and HYD groups than in the Infarct
group in comparison to the levels before surgery
in each group, but this increment was only
statistically significant in the HYD group in
comparison to the Infarct group (p<0.05).
DISCUSSION
The results of this study reveal that
exogenous hydrocortisone may provide a
protective effect in reducing the size of a
myocardial infarct in the “Rabbit heart model
of Ischemia-reperfusion”. This cardioprotective
effect was associated with a decreased Cardiac
Troponin-T (cTNT), ST-Segment, Infarct Area
(IA), Volume of Infarct Area and Infarcted area
to Area At risk ratio (IA/AAR).
The ability of hydrocortisone to reduce
infarct size in our study was in agreement with
other studies on glucocorticoids (Maclean et al.;
Kilger et al.; Johnson et al., 1953; Hepper et
al.; Barzilai et al., 1972), but with a difference
in that hydrocortisone in our study was more
effective than were the recent widely-used
synthetic analogues of corticosteroids,
dexamethasone and methylprednisolone
(Hafezi-Moghadam et al.; Enc et al.; Bourbon
et al., 2004). In the study by Hafezi-Moghadam
et al., dexamethasone reduced infarct size by
about 36.5%, while in our study hydrocortisone
produced about a 53% decrease, or a nearly 1.5
fold greater effect than that observed with
dexamethasone. With the use of salvaged
myocardium as an index of cardioprotective
efficacy, Maclean et al found hydrocortisone to
be more effective in comparison to
methylprednisolone (Maclean et al.), in
agreement with our results.
 In other studies, the stimulation of a
Glucocorticoid Receptor (GR) has been found
responsible for the decreased inflammatory
response and increased protective effects in
reducing the infarct size by synthetic analogues
of corticosteroids without high
mineralocorticoid potency (such as
Fig. 1. The trend in ST-segment elevation in experimental groups before major
ischemia and 60 min after onset of reperfusion. IP=Ischemic Preconditioning,
PP=Pharmacologic preconditioning, Data are expressed as the mean±SEM.
Fig. 2.  Planimetry of Myocardial tissue showing Infarcted Area /Area At Risk
ratio (IA/AAR Ratio); IP=Ischemic Preconditioning, PP=Pharmacologic
preconditioning;=Standard Error of Mean. *=significantly difference in
comparison to control group (P=0.05).  Data are expressed as the mean±SEM.
Fig. 3. Serum level of cardiac troponin-T (cTNT), before the onset of surgery
(cTNT-1) and after the end of reperfusion(cTNT-2). IP=Ischemic Preconditioning,
PP=Pharmacologic preconditioning,=Standard Error of Mean. There were no
significant differences between groups.  Data are expressed as the mean±SEM.
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Methylprednisolone and Dexamethasone) (Hafezi-Moghadam et al.;
Fillinger et al.; Bourbon et al.). Many studies have demonstrated that
myocardial tissue is capable of secreting glucoco- and
mineralocorticosteroids; as well, Mineralocorticoid Receptors (MR)
and an adrenal corticosteroid synthetase enzyme have been found in
myocardial tissue (Gómez-Sanchez & Gómez-Sanchez, 2001; White,
2003). In addition, the mineralocorticosteroid antagonist,
spironolactone, was shown to have deleterious consequences on the
protective effect of aldosterone in ischemia-reperfusion injury in
cultured rat cardiac fibroblasts (White). On the other hand, it is nota-
ble that natural glucocorticoids, such as hydrocortisone, have ten ti-
mes more affinity for binding to MR than do other synthetic analogues
(Sapolsky et al., 2000). These findings emphasize that cardioprotective
effects of corticosteroids are not related to their anti-inflammatory or
glucocorticoid actions; thus, these may be due to their mineralocorticoid
properties.  In this case, these findings are in agreement with our study
finding which emphasises that hydrocortisone efficacy is greater than
other corticosteroid synthetic analogues.
 Recently, it has been shown that synthetic corticosteroid
derivatives that lack anti-inflammatory and glucocorticoid effects
(Lazaroids) still have a substantial cardioprotective role. The major
mechanism of these agents is free radical scavenging (Takahashi et
al., 1998; Villa & Gorini, 1997), which implies that at least some
portion of the effects of cortisole are mediated by a different
mechanism. Another important finding of our study was the correlation
between the increment of endogenous cortisole and decrease of the
infarct size among the Infarct and IP Groups. Many studies have been
done to clarify the exact mechanism of ischemic preconditioning, and
have found that many endogenous factors such as adenosine, nitric
oxide, nuclear factors and ATP-dependent potassium channels are
involved in this phenomenon (Lochner et al., 1998; Lochner et al.,
2002; Armstrong et al., 2001). However, until now, there have been
no studies on the role of hydrocortisone in ischemic preconditioning.
 Munck et al. presented a model of glucocorticoid action that
includes stimulatory and suppressive effects of glucocorticoids on
endogenous stress responses. The model describes a bell-shaped curve,
with cortisole exerting stimulatory effects at lower
levels up to approximately 20 to 25mg/dL, whereas
at higher levels, suppressive glucocorticoid effects
become more prominent (Fillinger et al.). It has
also been proposed that natural glucocorticoids
have ten times more affinity for the
Mineralocorticoid Receptor that is responsible for
the permissive effects of glucocorticoids, and we
know that during the permissive action of
glucocorticoids, many endogenous peptides are
secreted, including opioids (Munck & Náray-
Fejes-Tóth, 1994). Therefore, as opioids have a
documented role in ischemic preconditioning
(Frässdorf et al., 2005), it is possible that
hydrocortisone exerts its cardioprotective effects
in ischemic preconditioning from an increased
release of these mediators.
 Preliminary studies have shown a direct
correlation between plasma levels of CK and CK-
MB and the severity of myocardial tissue damage
and myocardial infarction (Celik et al., 2004).
Giomarelli et al. (2003) concluded that preventive
administration of corticosteroids, by reducing
proinflammatory cytokine release and increasing
blood IL-10 levels, may provide a better degree
of myocardial protection. In our study, we did not
determine plasma levels of cytokines, but we did
measure the plasma levels of cTnT, which is more
accurate than
CK-MB for assessing myocardial
infarction. As a result, we can propose that the
protective effect of hydrocortisone in our study
may be related to a decreasing plasma level of
proinflammatory cytokines and/or an increase in
anti-inflammatory ones. Further studies are
needed to clarify the exact role of cytokines in
the protective mechanism afforded by
hydrocortisone.
In summary, we have shown that
hydrocortisone has cardioprotective effects when
injected before the onset of a myocardial
infarction. In addition, we have proposed for the
first time that endogenous hydrocortisone may
play a role in the ischemic preconditioning
phenomenon. Therefore, it is recommended that
more studies be designed to determine the exact
mechanism of endogenous hydrocortisone in
ischemic preconditioning, especially in relation to
mineralocorticoid action, free radical scavenging
and cytokine modulation.
Fig. 4. Serum Level of Cortisole before the onset of surgery (Cortisole-1) and
after the end of reperfusion(cortisole-2). IP=Ischemic Preconditioning,
PP=Pharmacologic preconditioning; Data are expressed as the mean±SEM.
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RESUMEN: La reducción del tamaño del infarto en el infarto agudo de miocardio es una de las metas más importantes que
impulsan la investigación y el desarrollo de nuevos fármacos. Durante las dos últimas décadas, muchos estudios clínicos han encontrado
efectos cardioprotectores de los corticosteroides, pero su papel exacto en el preacondicionamiento isquémico sigue siendo cuestionable.
El objetivo del presente estudio fue determinar los efectos protectores de succinato sódico de hidrocortisona en el preacondicionamiento
del miocardio en el corazón de conejo. Veinticuatro conejos neozelandeses machos fueron divididos al azar en  cuatro grupos : 1) control,
2) infarto, 3) preacondicionamiento isquémico (PI) y 4) Hidrocortisona (HYD). El grupo HYD recibió 50 mg/kg de hidrocortisona 45
minutos antes de la isquemia mayor. Los niveles séricos de troponina cardíaca T (cTNT) y cortisol se midieron antes y después de los
protocolos. Se utilizó la tinción cloruro de trifenil-tetrazolio para determinar el área infartada. En el presente estudio, la hidrocortisona
exógena disminuyó el tamaño del infarto en un 53% en comparación con el grupo de infarto. Los niveles séricos de cortisol se incrementaron
en los grupos IP y HYD, siendo significativa en el grupo de HYD (p <0,01). Un aumento en el nivel cortisol se asoció con la disminución
del tamaño del infarto y la cTNT en los grupos IP y HYD (p> 0,01). En conclusión, hemos demostrado la hidrocortisona tiene efectos
cardioprotectores cuando se inyecta antes de la aparición del infarto al miocardio. Además, hemos propuesto, por primera vez que la
hidrocortisona endógena puede jugar un papel en los fenómenos de preacondicionamiento isquémico.
PALABRAS CLAVE: Hidrocortisona; Tamaño del infarto; Modelo de isquemia-reperfusión; Preacondicionamiento
isquémico; Cortisol sérico.
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